Entries by Onc-admin

The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study

Dr Mymoona Alzouebi “It is estimated that one third of all cancer patients will require radiotherapy during their cancer journey. In the attached study, the data shows the impact the pandemic has had on radiotherapy services. Whilst some areas have seen significant reduction in radiotherapy treatments – cancers of the bladder, rectum and oesophagus witnessed […]

Maximizing rectal dose sparing with hydrogel: A retrospective planning study

Dr Mymoona Alzouebi “SpaceOAR© hydrogel (SOH) has been incorporated into the radiotherapeutic management of prostate cancer as a result of the proven benefits in reducing rectal toxicity and improving quality of life. In this study rectal dose sparing of greater than 25% was achieved in most post‐SpaceOAR© Hydrogel treatment plans generated in this planning study.”‍ […]

Management of locally advanced bladder cancer

Dr Omar Din “Bladder preservation with radiotherapy is an alternative to surgery for the management of locally advanced bladder cancer.  The results of this study show that hypofractionated radiotherapy over 20 fractions is as good as conventional radiotherapy over 32 fractions. This is good news for patients with a significantly shorter treatment time (4 weeks […]

Study into MR-Linac accelerator showing improved patient outcomes

This study shows that radiotherapy practitioners and members of hospital management expect to see improved patient outcomes. The majority of respondents in the study saw improved patient outcomes across 4 key areas Accurate targeting Real-time magnetic resonance imaging(MRI) means the MRIdian can show the exact position and shape of the tumour during treatment, so it […]

New drug available for metastic breast cancer

An ongoing main study (Destiny-Breast01) showed that Enhertu was effective at shrinking the tumour in patients with metastatic breast cancer or breast cancer that could not be removed by surgery. All patients had previously received two or more HER2-based treatments. Enhertu is used to treat breast cancer that is metastatic(has spread to other parts of the body) […]

ESMO: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

Researchers at UCLA’s Jonsson Comprehensive Cancer Center discovered that treating women with HER2-positive metastatic breast cancer with trastuzumab deruxtecan (T-DXd) significantly prolongs disease control and cancer growth compared to current standard of care, trastuzumab emtansine(T-DM1). T-Dxd is a HER2-targeted monoclonal antibody that delivers high doses of chemotherapy directly to cancer cells that express HER2. Compared […]


LUGANO, Switzerland – A novel combination of well-known drugs prolongs survival in patients with hormone/castration-sensitive prostate cancer, according to late breaking research presented at the ESMO Congress 2021. (1,2) The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone. Commenting on […]